abstract: BACKGROUND: Primary @entity1822 (PSL) are rare malignant lesions that are subdivided into cutaneous and subcutaneous @entity5 . Primary cutaneous and subcutaneous @entity1822 differ not only as to primary site of origins, but also to differences in prognosis. Guidelines for management and follow-up are not clearly defined in the literature. MATERIAL AND METHOD: Retrospective review was conducted from the @entity1 's chart between January 2000 and December 2009. Histopathology, immunohistochemistry, and clinical and surgical records were reviewed. RESULTS: The authors found five cases of PSL and divided them into two cases of @entity1822 and three cases @entity1822 . Overall, mean age of the @entity1 was 42.4 years, male: female ratio was 4:1. Clinical presentations were painless mass. Wide excisions were performed in three cases with 2 cm margins. No local recurrence was found in the period of follow-up (6 months to 3 years). One case presented with bony metastasis five years after operation. CONCLUSION: PSL are rare @entity5 . Surgical resection remains the main option for curative treatment. Wide excision with at least 2 cm peripheral margins and a depth that includes subcutaneous tissue and fascia are recommended. The natural history of these @entity5 is not clearly defined. All @entity1 should be followed-up for a period of at least five years after treatments. The authors hoped that further study of these @entity5 would result in better treatments and follow-up guidelines to be a benefit to such @entity1 in the future.

title: Clinicopathological study of primary XXXX .

entities_list: @entity5 :: ('MESH:D009369', 'Disease') :: ['tumors']

entities_list: @entity1 :: ('9606', 'Species') :: ['patients', 'patient']

entities_list: @entity1822 :: ('MESH:D007890', 'Disease') :: ['ofsubcutaneous leiomyosarcomas', 'cutaneous leiomyosarcomas', 'superficial leiomyosarcomas', 'leiomyosarcomas']

answer: @entity1822 :: (MESH:D007890,Disease) :: ['superficial leiomyosarcomas']


abstract: The effect of exogenous thyroid hormones (TH), @entity1955 (T4) or @entity1954 (T3), on spontaneous metamorphosis and serum T4 and T3 levels was examined in immediately premetamorphic @entity26962 ( @entity26962 ) from two populations. Size (> or = 120 mm in length and 3.0 g in weight) and a @entity4059 ( @entity4059 ) of > or = 1.50 were used to predict the number of larvae that were expected to metamorphose. The smallest size and lowest @entity4059 found in metamorphosing animals of each population (i.e., the minimum length, weight, and @entity4059 ) were also used in our assessment. Untreated larvae from Putnam Creek metamorphosed at a larger size (minimums; 134 mm, 4.12 g) than anticipated, out the minimum @entity4059 (1.59) and the incidence of metamorphosis (4/5 based on minimums) were consistent with results from the Salmon River population (minimums: 121 mm, 3.15 g, 1.54 @entity4059 , 8/9 metamorphosing). In the two experiments, T4-treated animals showed the predicted incidence of metamorphosis (2/2, 10/10), but significantly fewer larvae metamorphosed in the T3-treated groups (1/5, 5/11) than predicted. It was concluded that exogenous T3 administration affected the incidence of metamorphosis. In the treatment groups, serum TH levels in most nonmetamorphosing and metamorphosing animals were significantly higher than controls. Metamorphosing animals exposed to either TH had lower serum TH concentrations than nonmetamorphosing animals. A decline in serum TH levels is an early feature of metamorphosis in lampreys, but the artificial maintenance of elevated serum levels of TH cannot inhibit the decline in spontaneous metamorphosis. If the @entity308 of serum TH levels contributes to the initiation of metamorphic change, the magnitude of the decline is not a contributing factor.

title: Effects of exogenous XXXX (T4) and @entity1954 (T3) on spontaneous metamorphosis and serum T4 and T3 levels in immediately premetamorphic @entity26962 , @entity26962 .

entities_list: @entity308 :: ('MESH:D003866', 'Disease') :: ['depression']

entities_list: @entity4059 :: ('MESH:D007020', 'Disease') :: ['CF', 'condition factor']

entities_list: @entity1955 :: ('MESH:D013974', 'Chemical') :: ['thyroxine']

entities_list: @entity26962 :: ('7757', 'Species') :: ['Petromyzon marinus', 'sea lampreys']

entities_list: @entity1954 :: ('MESH:D014284', 'Chemical') :: ['triiodothyronine']

answer: @entity1955 :: (MESH:D013974,Chemical) :: ['thyroxine']


abstract: OBJECTIVE: To clarify whether assessment of the acoustic properties of the myocardium at rest can predict contractile reserve in @entity1 with @entity1002 . METHODS: 23 @entity1 (mean (SD) age 63 (12) years) with @entity1002 were studied. The magnitude of cardiac cycle dependent variation of integrated backscatter (CVIB) of the myocardium was measured at rest in the basal and mid segment of the septum and posterior wall of the left ventricle, using a real time two dimensional integrated backscatter imaging system. The results were compared with the percentage wall thickening and the wall motion at rest and during low dose @entity452 infusion. The wall motion was graded as normal, @entity5048 , or @entity2845 and contractile reserve was considered present when an @entity2845 or @entity5048 segment improved during @entity452 infusion. RESULTS: The CVIB at rest correlated with per cent wall thickening at rest and during @entity452 infusion (at rest, r = 0.61, p < 0.0001, during @entity452 , r = 0.76, p < 0.0001). Of the 76 segments examined, 27 showed contractile reserve. The mean CVIB at rest was significantly greater in segments with contractile reserve than in those without (p < 0.0001). CVIB above 3 dB at rest predicted segments with contractile reserve with a sensitivity and specificity of 81% and 60%, respectively (p < 0.0001). CONCLUSIONS: CVIB reflected not only myocardial contractility but also the functional capacity of the myocardium. It predicted segmental contractile reserve in @entity1 with @entity1002 .

title: Prediction of contractile reserve by cyclic variation of integrated backscatter of the myocardium in XXXX with @entity1002 .

entities_list: @entity1 :: ('9606', 'Species') :: ['patients']

entities_list: @entity452 :: ('MESH:D004280', 'Chemical') :: ['dobutamine']

entities_list: @entity5048 :: ('MESH:C536231', 'Disease') :: ['hypokinetic']

entities_list: @entity1002 :: ('MESH:D018487', 'Disease') :: ['chronic left ventricular dysfunction']

answer: @entity1 :: (9606,Species) :: ['patients']


abstract: BACKGROUND: Uterine artery embolization (UAE) is a safe and durable alternative to hysterectomy for the treatment of @entity2909 . Complications arising in the femoral artery puncture site such as @entity281 , @entity548 , and @entity1410 formation have been reported. This is the first report of @entity2849 formation following UAE. CASE: A 46-year-old primiparous @entity1 with multiple symptomatic @entity2909 became @entity101 during transfemoral UAE. The vascular sheath removal was delayed until blood pressure had normalized. Manual compression was required to control @entity548 from the right groin puncture site. A subcutaneous @entity1410 developed, extending down to the @entity1 's knee. Doppler ultrasound and CT arteriogram demonstrated a @entity397 . It was repaired by a vascular surgeon but became infected with @entity526 . The wound was healing well at three months after the procedure. CONCLUSION: Complications after UAE may be minimized by appropriate @entity1 selection, proper surgical technique, and appropriate monitoring and follow-up.

title: Femoral artery puncture site @entity2849 formation following uterine artery embolization for symptomatic XXXX : a case report.

entities_list: @entity1 :: ('9606', 'Species') :: ['woman', 'patient']

entities_list: @entity101 :: ('MESH:D006973', 'Disease') :: ['hypertensive']

entities_list: @entity548 :: ('MESH:D006470', 'Disease') :: ['bleeding']

entities_list: @entity281 :: ('MESH:D007239', 'Disease') :: ['infection']

entities_list: @entity397 :: ('MESH:D012421', 'Disease') :: ['ruptured pseudoaneurysm']

entities_list: @entity2849 :: ('MESH:D017541', 'Disease') :: ['pseudoaneurysm']

answer: @entity2909 :: (MESH:D007889,Disease) :: ['fibroids']


abstract: We previously demonstrated that an acidic variant (B1) of lysosomal @entity20109 from transplanted @entity1 @entity2 is phosphorylated on its protein and @entity1735 moieties (Gasa, S., and Makita, A. (1983) J. Biol. Chem. 258, 5034-5039). The present study identifies that a @entity268 -dependent protein kinase is responsible for phosphorylation of @entity20109 . The protein kinase activity toward the @entity18056 was considerably higher in the transplanted @entity2 than in normal lung in the presence of @entity268 . B enzyme purified from normal @entity1 liver was found to contain 0.6 mol/mol B enzyme, and protein kinase treatment added further 1.3 mol of Pi to give a single phosphopeptide (X). On the other hand, B1 enzyme purified from the transplanted @entity1 @entity2 which had been labeled in vivo with 32Pi revealed at least two phosphopeptides (X and Y). Assuming that the @entity18056 from normal @entity96 possesses the same number of available phosphorylation sites, phosphorylation of site X which was available only by deliberate phosphorylation of the native, ordinary B enzyme appears to be @entity5 -associated. Increasing phosphorylation of the @entity18056 resulted in a maximum 50% elevation in arylsulfatase activity, followed by a decrease of the activity upon overphosphorylation, using an artificial substrate.

title: Phosphorylation of XXXX lysosomal @entity20109 by @entity268 -dependent protein kinase. Different sites of phosphorylation between normal and @entity5 tissues.

entities_list: @entity20109 :: ('411', 'Gene') :: ['arylsulfatase B']

entities_list: @entity96 :: ('MESH:D008113', 'Disease') :: ['liver and lung cancer']

entities_list: @entity5 :: ('MESH:D009369', 'Disease') :: ['cancer']

entities_list: @entity2 :: ('MESH:D008175', 'Disease') :: ['lung cancer']

entities_list: @entity1735 :: ('CHEBI:16646', 'Chemical') :: ['carbohydrate']

answer: @entity1 :: (9606,Species) :: ['human']


abstract: BACKGROUND: We established short-term cultures of @entity5 from @entity1 with @entity703 for use as active specific immunotherapy (i.e., autologous vaccine). METHODS: Between 9/91 and 9/99 the cell biology laboratory of the Hoag Cancer Center received 69 @entity703 samples that had been surgically excised, including 43 @entity5 and 26 metastatic lesions. Efforts were made to establish short-term @entity5 cell cultures to use as @entity5 cell vaccines. Prior to treatment, @entity1 underwent a baseline skin test for @entity56 ( @entity56 ) and then received s.c. injections of 10 million @entity5 cells that were given with various adjuvants weekly x3 and then monthly x5. RESULTS: Cell lines were established for 55/69 @entity1 (80%) including 36/43 (84%) from @entity5 and 19/26 (73%) from distant metastases. Vaccines were prepared for 41 @entity1 ; 27 were treated. At the time of this analysis, follow up data was available for 26 @entity1 with a median follow up > 5 years. Treatment was well-tolerated. Of 10 @entity1 who had no evident disease at the time of treatment, nine were alive 1-8 years later; 5/8 had conversion of their @entity56 test from negative to positive. For 16 @entity1 with measurable metastatic disease at the time of treatment, there were no objective @entity5 responses; their median survival was 5.0 months. Among these 16 @entity1 , only 1/8 @entity56 tests converted, but three had a positive baseline @entity56 test; one was previously treated with @entity1199 and @entity5 infiltrating lymphocytes and two others were previously treated with autolymphocyte therapy. CONCLUSIONS: Vaccine therapy with short-term cultures of @entity5 cells is feasible, well-tolerated and associated with conversion of @entity56 and long-term survival in @entity1 who are free of disease at the time treatment is initiated. However, significant anti- @entity5 responses were not seen in @entity1 with measurable disease at the time vaccine treatment was initiated.

title: @entity703 with XXXX cell vaccines of short-term cell lines derived from renal cell carcinoma.

entities_list: @entity5 :: ('MESH:D009369', 'Disease') :: ['tumor', 'autologous tumor', 'primary tumors', 'autologous tumors', 'irradiated tumor']

entities_list: @entity56 :: ('MESH:D004342', 'Disease') :: ['DTH', 'delayed tumor hypersensitivity']

entities_list: @entity703 :: ('MESH:D007680', 'Disease') :: ['kidney tumor', 'renal carcinoma']

answer: @entity5 :: (MESH:D009369,Disease) :: ['autologous tumor']


abstract: @entity7373 ( @entity7373 ), or more simply L1, plays an important role in the progression of @entity1 @entity189 . Overexpression promotes @entity5 -cell invasion and motility, growth in @entity19 and @entity5 metastasis. It is feasible that L1-dependent signalling contributes to these effects. However, little is known about its mechanism in @entity5 cells. We reported previously that L1 is cleaved by ADAM (a disintegrin and metalloprotease) and that the cytoplasmic part is essential for L1 function. Here we analysed more closely the role of proteolytic cleavage in L1-mediated nuclear signalling. Using OVMz @entity189 cells and L1-transfected cells as a model, we found that @entity2854 -mediated cleavage of L1 proceeds in lipid raft and non-raft domains. The cleavage product, L1-32, is further processed by PS (presenilin)/gamma-secretase to release L1-ICD, an L1 intracellular domain of 28 kDa. Overexpression of dominant-negative @entity3666 or use of a specific gamma-secretase inhibitor leads to an accumulation of L1-32. Fluorescence and biochemical analysis revealed a nuclear localization for L1-ICD. Moreover, inhibition of @entity2854 and/or gamma-secretase blocks nuclear translocation of @entity7373 -dependent gene regulation. Overexpression of recombinant L1-ICD mediates gene regulation in a similar manner to full-length L1. Our results establish for the first time that regulated proteolytic processing by @entity2854 and PS/gamma-secretase is essential for the nuclear signalling of L1 in @entity1 @entity189 cell lines.

title: Nuclear translocation and signalling of @entity7373 in @entity1 XXXX cells requires @entity2854 and presenilin/gamma-secretase activity.

entities_list: @entity7373 :: ('3897', 'Gene') :: ['L1-CAM', 'L1 cell-adhesion molecule', 'L1-ICD and L1']

entities_list: @entity5 :: ('MESH:D009369', 'Disease') :: ['tumour']

entities_list: @entity189 :: ('MESH:D002277', 'Disease') :: ['carcinoma']

answer: @entity189 :: (MESH:D002277,Disease) :: ['carcinoma']


abstract: PURPOSE: To evaluate the long-term effectiveness of the combination of topical @entity205 drops and @entity1140 ointment in the treatment of @entity134 -dependent @entity9849 ( @entity9849 ). METHODS: Ten @entity1 with moderate to severe @entity9849 participated in the study. Topical @entity205 0.05% was used, as a monotherapy, 6 times daily during the first month of the study, followed by 4 times daily during the second month. The @entity1 were then instructed to self-treat with topical @entity205 at a dose ranging from 2 to 6 times daily depending on the severity of the disease. @entity1140 ointment 0.03% was applied on the lid skin. Follow-up examinations were performed approximately every 3 months. Each @entity1 completed a follow-up period of at least 12 months. Symptoms and signs of @entity9849 were assessed on the day of enrollment, on days 28, 56, and 63, and at subsequent follow-up visits. Flare-ups of @entity9849 requiring @entity134 use and progression of the disease findings were also recorded. RESULTS: All @entity1 experienced significant improvement of their symptoms and signs during the first 2 months of the study. Two @entity1 were lost to follow-up after the initial 2 months. One @entity1 was noncompliant and continued the treatment only for 7 months. During the median treatment period of 21.5 months for the 7 continuing @entity1 , a total of only 2 flare-up episodes were noted requiring topical @entity230 . CONCLUSIONS: Adequate topical immunomodulation using topical calcineurin inhibitors may eliminate the need for @entity230 and favorably alter the long-term prognosis of @entity1 with @entity9849 .

title: Topical calcineurin inhibitors in the treatment of @entity134 -dependent XXXX .

entities_list: @entity1 :: ('9606', 'Species') :: ['patients', 'patient']

entities_list: @entity9849 :: ('MESH:D007637', 'Disease') :: ['AKC', 'atopic keratoconjunctivitis']

entities_list: @entity134 :: ('CHEBI:35341', 'Chemical') :: ['steroid']

entities_list: @entity205 :: ('MESH:D016572', 'Chemical') :: ['cyclosporine']

entities_list: @entity1140 :: ('MESH:D016559', 'Chemical') :: ['Tacrolimus', 'tacrolimus']

entities_list: @entity230 :: ('MESH:D013256', 'Chemical') :: ['steroids']

answer: @entity9849 :: (MESH:D007637,Disease) :: ['atopic keratoconjunctivitis']


abstract: Exenatide (exendin-4) is an incretin mimetic with potential antidiabetic activity. This study examined the effects of a continuous subcutaneous (SC) infusion of exenatide (0.2, 0.4, 0.6, or 0.8 microg/kg/day) or placebo (PBO) on glycemic control over 23 h intervals. Twelve subjects with @entity164 2 @entity6 treated with @entity2449 and/or diet received 10 infusions (4 exenatide, 6 @entity20333 ) on consecutive days. Exenatide was given in a dose-increasing design with at least one placebo infusion between each exenatide infusion, and with meals and a snack provided during the first 14 h of infusion. Plasma exenatide concentrations were dose-proportional. Plasma @entity413 (4-23 h) was lower in all exenatide arms compared to placebo (p<0.0001). The change in insulin/glucagon ratio and @entity2532 concentrations from pre-infusion to post-infusion was increased (p<0.005, p<0.05, respectively) in the combined exenatide arms, but remained unchanged in the placebo groups. @entity1209 were the most common treatment emergent adverse events. Exenatide infusion also appeared to have positive effects on beta-cell and alpha-cell function as measured by @entity2690 /insulin ratios and mean glucagon concentrations. In summary, exenatide lowered plasma @entity413 during both prandial and fasting states when delivered as a continuous SC infusion over twenty-three hours, suggesting that exenatide can provide day-long glycemic control in @entity1 with @entity164 2 @entity6 .

title: Day-long subcutaneous infusion of exenatide lowers glycemia in XXXX with @entity164 2 @entity6 .

entities_list: @entity1 :: ('9606', 'Species') :: ['patients']

entities_list: @entity6 :: ('MESH:D003920', 'Disease') :: ['diabetes']

entities_list: @entity1209 :: ('MESH:D020250', 'Disease') :: ['Nausea and vomiting']

entities_list: @entity413 :: ('MESH:D005947', 'Chemical') :: ['glucose']

entities_list: @entity2449 :: ('MESH:D008687', 'Chemical') :: ['metformin']

answer: @entity1 :: (9606,Species) :: ['patients']


abstract: BACKGROUND: Metallic implants, stents, are increasingly being used especially in @entity1 with @entity850 of the cardiac vessels. Ten to thirty per cent of the @entity1 suffer from @entity256 regardless of aetiology. We have shown increased frequency of contact @entity566 to stent metals in stented @entity1 . OBJECTIVES: To we evaluate whether contact @entity566 to stent material is a risk factor for @entity256 . METHODS: @entity1 with stainless steel stents, with or without gold plating, were epicutaneously tested and answered a questionnaire. The @entity256 rate was evaluated. RESULTS: We found a correlation between contact @entity566 to gold, gold stent, and @entity256 (OR 2.3, CI 1.0-5.1, P = 0.04). The risk for @entity256 was threefold increased when the @entity1 was gold @entity56 and stented with a gold-plated stent. An increased degree of @entity662 in gold- @entity56 @entity1 stented with gold-plated stent was found. CONCLUSIONS: We found a correlation between contact @entity566 to gold, gold-stent, and @entity256 . It may be of importance to consider contact @entity566 when developing new materials for stenting.

title: A correlation found between contact XXXX to stent material and @entity256 of the coronary arteries.

entities_list: @entity1 :: ('9606', 'Species') :: ['Patients', 'patients', 'patient']

entities_list: @entity662 :: ('MESH:D002637', 'Disease') :: ['chest pain']

entities_list: @entity256 :: ('MESH:D023903', 'Disease') :: ['restenosis']

entities_list: @entity56 :: ('MESH:D004342', 'Disease') :: ['allergic']

entities_list: @entity850 :: ('MESH:D003251', 'Disease') :: ['stenosis']

answer: @entity566 :: (MESH:D006967,Disease) :: ['allergy']


abstract: BACKGROUND: The @entity2271 ( @entity2272 ) pathway plays an important role in the plants' reaction to drought stress and ABA-stress response (Asr) genes are important in controlling this process. In this sense, we accessed @entity377 diversity at two candidate genes for drought tolerance (Asr1 and Asr2), involved in an ABA signaling pathway, in the reference collection of cultivated common bean ( @entity11297 .) and a core collection of wild common bean accessions. RESULTS: Our wild population samples covered a range of mesic (semi-arid) to very dry (desert) habitats, while our cultivated samples presented a wide spectrum of drought tolerance. Both genes showed very different patterns of @entity377 variation. Asr1 exhibited very low @entity377 diversity relative to the neutral reference loci that were previously surveyed in these populations. This suggests that strong purifying selection has been acting on this gene. In contrast, Asr2 exhibited higher levels of @entity377 diversity, which is indicative of adaptive selection. These patterns were more notable in wild beans than in cultivated common beans indicting that natural selection has played a role over long time periods compared to farmer selection since domestication. CONCLUSIONS: Together these results suggested the importance of Asr1 in the context of drought tolerance, and constitute the first steps towards an association study between genetic polymorphism of this gene family and variation in drought tolerance traits. Furthermore, one of our major successes was to find that wild common bean is a reservoir of genetic variation and selection signatures at Asr genes, which may be useful for breeding drought tolerance in cultivated common bean.

title: Molecular ecology and selection in the drought-related Asr gene polymorphisms in wild and cultivated common bean ( XXXX .).

entities_list: @entity2271 :: ('MESH:D000040', 'Chemical') :: ['abscisic acid']

entities_list: @entity11297 :: ('3885', 'Species') :: ['Phaseolus vulgaris L']

entities_list: @entity377 :: ('CHEBI:36976', 'Chemical') :: ['nucleotide']

answer: @entity11297 :: (3885,Species) :: ['Phaseolus vulgaris L']


abstract: The aim of this study was to evaluate portal vein and bile duct @entity137 after stereotactic body radiation therapy (SBRT) for @entity157 ( @entity157 ). We retrospectively reviewed 63 @entity1 who were administrated SBRT once for @entity157 . The prescribed doses were from 48   Gy in four fractions to 60   Gy in eight fractions. @entity715 and @entity1157 were evaluated. The dose received by 2% of the volume (D2 ) of the portal vein and bile duct was calculated. @entity715 was observed in three @entity1 (4.8%). Common points of these @entity1 were @entity1 -Pugh class B and D2 of the portal vein 40   Gy or more (BED3 >= 200   Gy). @entity1157 was observed in one @entity1 (1.6%). The @entity1 had a history of @entity201 and @entity99 . @entity715 may be necessary to be considered when SBRT for @entity157 is administrated to @entity1 in higher @entity1 -Pugh class with higher D2 of the portal vein.

title: Case reports of @entity715 and XXXX after stereotactic body radiation therapy for @entity157 .

entities_list: @entity1 :: ('9606', 'Species') :: ['Child', 'patients', 'patient']

entities_list: @entity137 :: ('MESH:D064420', 'Disease') :: ['toxicity']

entities_list: @entity1157 :: ('MESH:D001649', 'Disease') :: ['bile duct stenosis', 'Bile duct stenosis']

entities_list: @entity201 :: ('MESH:D018281', 'Disease') :: ['cholangiocarcinoma']

entities_list: @entity157 :: ('MESH:D006528', 'Disease') :: ['HCC', 'hepatocellular carcinoma']

entities_list: @entity99 :: ('MESH:D056486', 'Disease') :: ['left hepatic lobectomy']

entities_list: @entity715 :: ('MESH:D013927', 'Disease') :: ['Portal vein thrombosis']

answer: @entity1157 :: (MESH:D001649,Disease) :: ['bile duct stenosis']


abstract: @entity378 of the middle ear is rare; associated @entity693 is even more unusual. This report contains our experience with a one and a half year old @entity1155 @entity1 . He had a poor healing left @entity733 four months prior to admission. Also noted was postprandial vomiting and left sided involuntary movement. On admission spinal tapping was done. Results showed @entity491 , with lymphocytes being predominant, as well as high protein and low @entity413 levels. A cranial CT revealed left @entity2267 , @entity1276 , basal cistern abnormal enhancement and a prominent posterior fossa postcerebellar @entity2841 space. Left radical mastoidectomy was performed. A biopsy showed caseous @entity39 surrounded by epitheloid and Langhan's giant cells. He also received a ventriculoperitoneal shunt. The gastric and @entity2841 were both positive for tuberculous culture.

title: [ @entity378 media, @entity2267 associated with XXXX : report of one case].

entities_list: @entity1276 :: ('MESH:D006849', 'Disease') :: ['hydrocephalus']

entities_list: @entity39 :: ('MESH:D009336', 'Disease') :: ['necrosis']

entities_list: @entity693 :: ('MESH:D008581', 'Disease') :: ['meningitis']

entities_list: @entity733 :: ('MESH:D000038', 'Disease') :: ['postauricular abscess']

entities_list: @entity2267 :: ('MESH:D008417', 'Disease') :: ['mastoiditis']

entities_list: @entity1155 :: ('MESH:D011596', 'Disease') :: ['psychomotor retarded']

entities_list: @entity413 :: ('MESH:D005947', 'Chemical') :: ['glucose']

entities_list: @entity378 :: ('MESH:D014376', 'Disease') :: ['Tuberculosis']

entities_list: @entity491 :: ('MESH:D007964', 'Disease') :: ['leukocytosis']

answer: @entity693 :: (MESH:D008581,Disease) :: ['meningitis']


abstract: @entity19 bone marrow Thy-1lo, Lin-, @entity3513 + cells have been isolated by fluorescence-activated cell sorting (FACS). This population contained up to 27% in vitro colony-forming cells (CFC) when stimulated by @entity3019 ) and 5% day-12 spleen colony-forming units (CFU-S) (uncorrected for seeding efficiency). As few as 100 cells were able to reconstitute the @entity2800 and lymphoid compartments of lethally irradiated recipients for periods of up to 72 weeks. Over the range of 30-560 transplanted cells, three patterns of engraftment were observed; the proportion of donor cells increased gradually to values of > 90%, gradually declined, or remained static over the 72-week observation period. When the donor cell percentage in the peripheral blood exceeded 60%, both @entity2800 (neutrophils and monocytes) and lymphoid (T- and B-lymphocytes) cells were of donor origin. Primary animals containing > 60% donor cells in their peripheral blood were able to engraft secondary recipients with donor cells of both @entity2800 and lymphoid lineages. Primary animals with < 20% donor cells in their peripheral blood contained bone marrow cells that were only able to produce lymphoid cells in the peripheral blood of secondary recipients. With > 90% of animals, including both primary and secondary recipients, there were no large fluctuations in the proportion of donor @entity2800 or lymphoid cells in the peripheral blood. Where changes occurred, with three exceptions, these were gradual. These data suggest that the Thy-1lo, Lin-, @entity3513 + population is heterogeneous and contains in vitro CFC, day-12 CFU-S, and long-term repopulating cells for both the @entity2800 and lymphoid lineages and cells capable of long-term repopulation of only the lymphoid lineage.

title: Long-term hemopoietic repopulation by Thy-1lo, Lin-, XXXX + cells.

answer: @entity3513 :: (110454(Tax:10090),Gene) :: ['Ly6A/E']


abstract: The effects of beta 2- and beta 1-adrenoceptor (beta 2AR and beta 1AR, respectively) agonists on the cytosolic @entity141 (Cai) transient (indexed by the transient increase in indo-1 fluorescence ratio after excitation), twitch amplitude (measured via photodiode array), membrane potential, and L-type sarcolemmal @entity141 current (ICa, measured by whole-cell patch electrode) were assessed in single @entity35 ventricular myocytes. The selective beta 2AR agonist @entity42828 increased the amplitudes of both the Cai transient and twitch in a concentration-dependent manner. Similar results were obtained when beta 2ARs were stimulated with @entity3044 in the presence of the selective beta 1AR antagonist @entity14528 . beta 1AR stimulation induced by @entity1063 increased twitch amplitude to about the same extent as did beta 2AR stimulation. However, several striking differences between response to beta 1AR and beta 2AR stimulation were observed. beta 1AR stimulation had the potent effect of abbreviating the time course of the contraction and Cai transient, and beta 2AR stimulation did not reduce the time course of the Cai transient and had only a minor effect on the twitch duration. For a given increase in twitch amplitude, beta 1AR stimulation caused a greater increase in Cai transient, suggesting a diminished Cai-myofilament interaction. beta 1AR, but not beta 2AR, stimulation evoked spontaneous Cai oscillations, increased the diastolic indo fluorescence level, and caused a decline in resting cell length. beta 1AR and beta 2AR also differed in their effects on ICa. Whereas both beta 1AR and beta 2AR stimulation increased the peak ICa amplitude, beta 2AR stimulation markedly prolonged the ICa inactivation time. Accordingly, beta 2AR stimulation prolonged the action potential duration to a greater extent than did beta 1AR stimulation. @entity17174 mimicked the effects of beta 1AR stimulation by @entity1063 but not those due to beta 2AR stimulation. These results clearly indicate that both beta 2ARs and beta 1ARs functionally coexist in @entity35 ventricular myocytes but that stimulation of these receptor subtypes elicits qualitatively different cell responses at the levels of ionic channels, the myofilaments, and sarcoplasmic reticulum.

title: Beta 1-adrenoceptor stimulation and beta 2-adrenoceptor stimulation differ in their effects on contraction, cytosolic XXXX , and @entity141 current in single @entity35 ventricular cells.

entities_list: @entity3044 :: ('MESH:D007545', 'Chemical') :: ['isoproterenol']

entities_list: @entity17174 :: ('MESH:C015929', 'Chemical') :: ['8-(4-Chlorophenylthio)cAMP']

entities_list: @entity1063 :: ('MESH:D009638', 'Chemical') :: ['norepinephrine']

answer: @entity141 :: (CHEBI:29108,Chemical) :: ['Ca2+']


abstract: BACKGROUND: The aim of our study was to compare healthcare-related costs of treatment with XELOX and FOLFOX4 chemotherapeutic regimens in @entity1 with @entity14 . We have evaluated costs claimed to the health insurance by the hospital administering these @entity5 therapies. This study is a pilot project utilising the new I-COP database developed by the Institute of Biostatistics and Analyses of the Masaryk University in Brno, Czech Republic. @entity1 AND METHODS: First, we estimated the costs based on current prices of procedures, medication, and materials from public sources. Using the I-COP database, we then carried out a matched-pair comparison of 26 @entity1 treated with FOLFOX4 or XELOX for @entity14 . We evaluated a period of three months of therapy (i.e. 6 cycles of FOLFOX4 or 4 cycles of XELOX). Statistical analysis was done using the Wilcoxon matched pairs test. RESULTS: The estimated cost for three months of therapy was 148,288 Czech crowns (CZK) for FOLFOX4 (including CZK 101,064 for chemotherapy drugs) and CZK 123,756 for XELOX. The overall costs claimed to the insurance companies were CZK 160,158 and CZK 151,176 for FOLFOX4 and XELOX, respectively (p = 0.221). The XELOX regimen had significantly higher costs for chemotherapy drugs (CZK 131,705 versus 114,531, p = 0.023) whereas other costs were lower than those for FOLFOX4. CONCLUSIONS: FOLFOX4 and XELOX regimens can be considered as equivalent in terms of costs claimed by the hospital administering @entity5 treatment.

title: [Cost analysis of XELOX and FOLFOX-4 chemotherapy regimens for XXXX ].

entities_list: @entity1 :: ('9606', 'Species') :: ['patients', 'PATIENTS']

entities_list: @entity5 :: ('MESH:D009369', 'Disease') :: ['cancer']

entities_list: @entity14 :: ('MESH:D015179', 'Disease') :: ['colorectal cancer']

answer: @entity14 :: (MESH:D015179,Disease) :: ['colorectal carcinoma']


abstract: We report a case of a 19-year-old @entity1 who developed a persistent uterine @entity548 after spontaneous delivery of a healthy @entity1 . Emergency laparotomy was indicated and then begun under stable circulatory conditions. @entity1167 occurred during the course of massive manual compression and packing of the uterus. After successful resuscitation, a supracervical hysterectomy was performed. During the suturing of the remaining cervix, a second @entity1167 followed. The procedure was completed under constant external heart massage. Resuscitation was terminated due to the persistence of widened pupils. An autopsy was ordered by the public prosecutor as the manner of @entity204 was declared to be unascertained. An X-ray and a CT scan prior to the autopsy showed @entity3728 in both arterial and venous vessels extending from the pelvic region to the head. During the autopsy, gas was collected by aspirometer from the right ventricle of the heart. The autopsy showed no additional relevant findings, and gas analysis confirmed the suspicion of air @entity887 . The histological examination of the excised uterus especially in the corpus/fundus revealed an @entity4 of the local smooth muscle cells and dilated vessels showing no sign of thrombogenesis. Upon evaluation of the clinical records, it became evident that, in addition to uterine atony, there had been a complete uterine inversion. This inversion was manually repositioned. After this maneuver, manual compression was performed. The air @entity887 , thus, was a complication of the manual repositioning of the uterine inversion. There is no evidence for other possible entries of the detected gas. In order to perform an effective exploration, the availability of all clinical records should be mandatory for medico-legal investigations of unexpected postpartum deaths.

title: Fatal postpartum air XXXX due to uterine inversion and @entity548 .

entities_list: @entity3728 :: ('MESH:D004618', 'Disease') :: ['extensive gas embolism']

entities_list: @entity548 :: ('MESH:D006470', 'Disease') :: ['hemorrhage']

entities_list: @entity887 :: ('MESH:D004617', 'Disease') :: ['embolism']

entities_list: @entity1167 :: ('MESH:D006323', 'Disease') :: ['cardiac arrest', 'Cardiac arrest']

answer: @entity887 :: (MESH:D004617,Disease) :: ['embolism']


abstract: PURPOSE: We assessed the near term comfort of newly designed ureteral study stents or marketed control stents, including Polaris and Percuflex stents. Study stents had distal 6Fr pigtail ends with 3Fr or less loops. Decreased material in situ was hypothesized to enhance comfort. Usefulness of the @entity1 self-administered Ureteral Stent Symptoms Questionnaire (Stone Management Unit, Southmead Hospital, United Kingdom) was assessed. MATERIALS AND METHODS: This 4-arm multicenter study enrolled adults requiring retrograde unilateral ureteral stent placement for 4 to 28 days. Ureteral Stent Symptoms Questionnaire administration was done before placement (baseline), on day 4 after placement and on day 30 after removal. A total of 236 @entity1 were randomized in a 1:1:1:1 ratio to the short loop tail stent (60), the long loop tail stent (59), the Percuflex Plus stent (64) and the Polaris stent (53). RESULTS: Overall @entity158 worsened from baseline to day 4 and improved from days 4 to 30. Mean @entity158 medication use peaked for all stents on day 1 after placement. Common device related symptoms were mild or moderate in severity, including @entity812 in 47 @entity1 , @entity811 in 39, @entity3833 in 34, frequent urination in 30 and urinary urgency in 27. Six @entity1 experienced a total of 9 device related adverse events requiring hospitalization. All adverse events resolved, including most within 3 days of inpatient treatment. CONCLUSIONS: Although it was not statistically significant, @entity1 stented with the short loop tail had lower questionnaire @entity158 scores on day 4 after placement and lower @entity158 medication use on day 1 after placement when @entity158 peaked in all stent groups, suggesting that ureteral stent comfort, especially @entity158 , may be improved by less material in situ. The Ureteral Stent Symptoms Questionnaire may be better suited for longer term comparisons in stented vs nonstented @entity1 , rather than in this short-term ureteral stent trial.

title: Assessing the impact of ureteral stent design on XXXX comfort.

entities_list: @entity1 :: ('9606', 'Species') :: ['patients', 'patient']

entities_list: @entity812 :: ('MESH:D021501', 'Disease') :: ['flank pain']

entities_list: @entity811 :: ('MESH:D006417', 'Disease') :: ['hematuria']

answer: @entity1 :: (9606,Species) :: ['patient']


abstract: Aspartoacylase catalyzes the deacetylation of @entity6284 ( @entity14728 ) to produce @entity598 and @entity14424 and is the only brain enzyme that has been shown to effectively metabolize @entity14728 . Although the exact role of this enzymatic reaction has not yet been completely elucidated, the metabolism of @entity14728 appears to be necessary in the formation of myelin lipids, and defects in this enzyme lead to @entity7495 , a fatal @entity16 . The low catalytic activity and inherent instability observed with the @entity526 -expressed form of aspartoacylase suggested the need for a suitable eukaryotic expression system that would be capable of producing a fully functional, mature enzyme. @entity1 aspartoacylase has now been successfully expressed in @entity10056 . While the expression yields are lower than in @entity526 , the purified enzyme is significantly more stable. This enzyme form has the same substrate specificity but is 150-fold more active than the @entity526 -expressed enzyme. The molecular weight of the purified enzyme, measured by mass spectrometry, is higher than predicted, suggesting the presence of some post-translational modifications. Deglycosylation of aspartoacylase or mutation at the glycosylation site causes decreased enzyme stability and diminished catalytic activity. A @entity1735 component has been removed and characterized by mass spectrometry. In addition to this @entity1735 moiety, the enzyme has also been shown to contain one @entity219 atom per subunit. Chelation studies to remove the @entity219 result in a reversible loss of catalytic activity, thus establishing aspartoacylase as a @entity219 metalloenzyme.

title: Characterization of @entity1 aspartoacylase: the brain enzyme responsible for XXXX .

entities_list: @entity10056 :: ('4922', 'Species') :: ['Pichia pastoris']

entities_list: @entity6284 :: ('CHEBI:21547', 'Chemical') :: ['N-acetylaspartic acid']

entities_list: @entity16 :: ('MESH:D009422', 'Disease') :: ['neurological disorder']

entities_list: @entity598 :: ('CHEBI:47622', 'Chemical') :: ['acetate']

entities_list: @entity1735 :: ('CHEBI:16646', 'Chemical') :: ['carbohydrate']

entities_list: @entity7495 :: ('MESH:D017825', 'Disease') :: ['Canavan disease']

entities_list: @entity14424 :: ('CHEBI:29991', 'Chemical') :: ['L-aspartate']

entities_list: @entity526 :: ('562', 'Species') :: ['Escherichia coli', 'E. coli']

answer: @entity7495 :: (MESH:D017825,Disease) :: ['Canavan disease']


abstract: Prior work demonstrated the improvement of peripheral nerve regeneration in gaps implanted with collagen scaffold-filled collagen tubes, compared with nerve autografts, and the promise of such implants for treating gaps in @entity1566 ( @entity1566 ) in @entity35 . The objective of this study was to investigate collagen implants alone and incorporating select therapeutic agents in a 5-mm full-resection gap model in the @entity35 spinal cord. Two studies were performed, one with a 6-week time point and one with a 2-week time point. For the 6-week study the groups included: (1) untreated control, (2) dehydrothermally ( @entity587 )-cross-linked collagen scaffold, (3) @entity587 -cross-linked collagen scaffold seeded with adult @entity35 neural stem cells (NSCs), and (4) @entity587 -cross-linked collagen scaffold incorporating plasmid encoding glial cell line-derived neurotropic factor (pGDNF). The 2-week study groups were: (1) nontreated control, (2) @entity587 -cross-linked collagen scaffold; (3) @entity587 -cross-linked collagen scaffold containing laminin; and (4) @entity26408 -cross-linked collagen scaffold containing laminin. The tissue filling the defect of all groups at 6 weeks was largely composed of @entity82 ; however, the tissue was generally more favorably aligned with the long axis of the spinal cord in all of the treatment groups, but not in the control group. Quantification of the percentage of animals per group containing cystic cavities in the defect showed a trend toward fewer @entity35 with cysts in the groups in which the scaffolds were implanted compared to control. All of the collagen implants were clearly visible and mostly intact after 2 weeks. A band of fibrous tissue filling the control gaps was not seen in the collagen implant groups. In all of the groups there was a narrowing of the spinal canal within the gap as a result of surrounding soft tissue collapse into the defect. The narrowing of the spinal canal occurred to a greater extent in the control and @entity587 scaffold alone groups compared to the @entity587 scaffold/laminin and EDAC scaffold/laminin groups. Collagen biomaterials can be useful in the treatment of @entity1566 to: favorably align the reparative tissue with the long axis of the spinal cord; potentially reduce the formation of fluid-filled cysts; serve as a delivery vehicle for NSCs and the gene for @entity10157 ; and impede the collapse of musculature and connective tissue into the defect.

title: The reparative response to cross-linked collagen-based scaffolds in a XXXX spinal cord gap model.

entities_list: @entity82 :: ('MESH:D005355', 'Disease') :: ['fibrous scar']

entities_list: @entity26408 :: ('CHEBI:53091', 'Chemical') :: ['carbodiimide']

entities_list: @entity1566 :: ('MESH:D013119', 'Disease') :: ['spinal cord injury', 'SCI']

answer: @entity35 :: (10116,Species) :: ['rat']


abstract: Cephalic-vagal stimulation affects a number of upper gastrointestinal secretory and motility events. The purpose of this study was to examine the role of vagal-cholinergic regulation on @entity1 proximal duodenal mucosal HCO-3 secretion. The duodenal bulb was isolated between balloons and perfused with 154 mM @entity1219 , and HCO-3 secretion was measured. Although cholinergic stimulation with @entity10257 (50 micrograms.kg-1.h-1 iv) produced systemic effects, resting HCO-3 secretion was unchanged. Cephalic-vagal stimulation, induced by sham feeding, significantly increased duodenal HCO-3 secretion from a basal of 177 +/- 17 to 240 +/- 19 mumols.cm-1.h-1 (P less than 0.02). The response to sham feeding was approximately 50% of the peak response to acid-stimulated HCO-3 output. @entity3897 (22 micrograms/kg iv) inhibited basal HCO-3 secretion significantly (79 +/- 5%). However, the net incremental increases in duodenal mucosal HCO-3 secretion in response to luminal acidification and vagal stimulation were unaltered by @entity3897 pretreatment. Additionally, @entity3352 (100 mg po) failed to modify the response to vagal-stimulated HCO-3 secretion. These findings indicate that basal @entity1 proximal duodenal mucosal HCO-3 secretion is maintained largely by resting cholinergic innervation and is stimulated by cephalic-vagal stimulation. Furthermore, since the incremental HCO-3 responses to cephalic-vagal stimulation and luminal acidification were unaltered by @entity3897 pretreatment, each is likely mediated by noncholinergic mechanisms.

title: Cholinergic regulation of XXXX proximal duodenal mucosal bicarbonate secretion.

entities_list: @entity3897 :: ('MESH:D001285', 'Chemical') :: ['Atropine', 'atropine']

entities_list: @entity3352 :: ('MESH:D007213', 'Chemical') :: ['indomethacin']

entities_list: @entity10257 :: ('MESH:D018723', 'Chemical') :: ['bethanechol']

answer: @entity1 :: (9606,Species) :: ['human']


abstract: GOALS OF WORK: Even though a lot of studies have been conducted concerning @entity5 @entity1 ' social support, the importance of social support from the work life is unclear. We examined the amount of emotional and practical support that @entity5 survivors needed and had actually received from their coworkers, supervisors, and the occupational health personnel. We also examined whether disease-related or sociodemographic background variables were associated with needed or received support. Finally, we investigated whether there were differences between various sources in received or needed support. @entity1 AND METHODS: The data consisted of a total of 640 @entity5 survivors with @entity0 , @entity263 , aged 25-57 years at the time of diagnosis. Information on social support was collected with a mailed questionnaire using an adapted version of the Structural-Functional Social Support Scale (SFSS). MAIN RESULTS: The @entity5 survivors had received most support from their coworkers and they hoped for more support especially from the occupational health care personnel (39% of @entity1 and 29% of @entity1 ). The @entity1 who had @entity706 , had received chemotherapy, or had low education level needed more support. The need for practical support from the occupational health personnel was fivefold between the chemotherapy-treated and those not treated. The @entity1 both received and needed more support than the @entity1 did. CONCLUSIONS: There is a clear need for additional social support from work life among the @entity5 survivors especially from the occupational health personnel.

title: XXXX survivors' received and needed social support from their work place and the occupational health services.

entities_list: @entity1 :: ('9606', 'Species') :: ['women', 'patients', 'PATIENTS', 'men']

entities_list: @entity263 :: ('MESH:D011471', 'Disease') :: ['testicular or prostate cancer']

entities_list: @entity0 :: ('MESH:D001943', 'Disease') :: ['breast cancer, lymphoma']

entities_list: @entity706 :: ('MESH:D008223', 'Disease') :: ['lymphoma']

entities_list: @entity5 :: ('MESH:D009369', 'Disease') :: ['cancer']

answer: @entity5 :: (MESH:D009369,Disease) :: ['Cancer']


abstract: We have shown earlier that the @entity2391 and @entity1968 (RA) combination, but not the single agents, induces @entity204 in several @entity5 cell lines. Employing a genetic technique we have identified several Genes associated with Retinoid-IFN induced Mortality (GRIM). One of the GRIMs was @entity1 @entity19877 ( @entity19877 ), a redox enzyme. Since the overexpressed @entity19877 augments IFN/RA stimulated cell @entity204 , we explored the mechanisms of @entity19877 -mediated @entity204 . Here we show that TR augments cell @entity204 by upregulating the transcriptional activity of @entity876 @entity5 suppressor. This process does not involve a physical increase in levels of @entity876 . Using redox inactive mutants of @entity19877 and its substrate, @entity14688 ( @entity14688 ), we demonstrate that IFN/RA-induced regulation of @entity876 dependent gene expression requires TR and @entity14688 . In contrast-over-expression of wildtype @entity19877 or @entity14688 augment the @entity876 dependent gene expression in response to IFN/RA treatment. Consistent with these results an increased DNA binding activity of @entity876 was noted in the presence of TR. These studies identify a novel mechanism of @entity876 mediated cell @entity204 regulation involving redox enzymes.

title: Modulation of @entity876 dependent gene expression and cell XXXX through @entity14688 - @entity14688 reductase by the Interferon-Retinoid combination.

entities_list: @entity19877 :: ('25824', 'Gene') :: ['thioredoxin reductase', 'TR']

entities_list: @entity1968 :: ('MESH:D014212', 'Chemical') :: ['all-trans retinoic acid']

answer: @entity204 :: (MESH:D003643,Disease) :: ['death']


abstract: BACKGROUND: The aim of the study was to determine the most common treatment strategies and their costs for @entity1 with an inadequate response to first-line @entity34 ( @entity34 ) in primary care. METHOD: A retrospective cohort study of medical records from six primary care centers was conducted. Adults with a major @entity308 diagnosis, at least 8   weeks of @entity34 treatment after the first prescription, and @entity1 monitoring for 12   months were analyzed. Healthcare (direct cost) and non-healthcare costs (indirect costs; work productivity losses) were described. RESULTS: A total of 2,260 @entity1 were studied. Forty-three percent of @entity1 (N   =   965) presented an inadequate response to treatment. Summarizing the different treatment approaches: 43.2% were switched to another @entity34 , 15.5% were given an additional @entity34 , @entity34 dose was increased in 14.6%, and 26.7% remained with the same antidepressant agent. Healthcare/annual costs were 451.2 @entity7634 for @entity1 in remission vs. 826.1 @entity7634 in those with inadequate response, and productivity losses were 991.4 versus 1,842.0 @entity7634 , respectively (p   <   0.001). CONCLUSION: Antidepressant switch was the most common therapeutic approach performed by general practitioners in naturalistic practice. A delay in treatment change when no remission occurs and a significant heterogeneity in management of these @entity1 were also found.

title: Assessment of pharmacological strategies for management of major XXXX and their costs after an inadequate response to first-line @entity34 in primary care.

entities_list: @entity1 :: ('9606', 'Species') :: ['patients', 'patient']

entities_list: @entity308 :: ('MESH:D003866', 'Disease') :: ['depressive disorder']

entities_list: @entity34 :: ('MESH:D016609', 'Disease') :: ['antidepressant treatment', 'AD']

answer: @entity308 :: (MESH:D003866,Disease) :: ['depressive disorder']


abstract: OBJECTIVE: To investigate the incidence of @entity43 in @entity5 , especially in early FIGO stages. METHODS: Seventeen @entity5 @entity1 with @entity43 treated at Cancer Hospital, Chinese Academy of Medical Sciences from 1958 to 1994 were retrospectively analysed. The diagnoses of all @entity1 were confirmed by operations and pathologic examinations. RESULTS: The incidence of @entity43 in @entity5 was 0.07% in @entity957 and 1.81% in @entity420 (P < 0.05). In early stages (stage l-I), the incidence of @entity43 in @entity420 was higher than that in @entity957 (2.2% VS 0.08%, P < 0.05). In @entity1 treated by surgery, the rate of @entity43 in @entity420 was also higher than that in @entity957 (7.8% VS 1.6%, P < 0.05). 10 of the 17 cases had macroscopic @entity3 and 7 had microscopic @entity3 . 11 @entity1 (58.8%) were with bilateral ovarian involvement. Uterine corpus invasion and retroperitoneal lymph node involvements were high risk factors for @entity43 in @entity5 . The prognosis of @entity5 @entity1 with @entity43 was poor, the 5-year survival rate in this study being only 17.6%. CONCLUSIONS: @entity1 with @entity5 are threatened with the risk of @entity43 , especially in @entity420 . Conservative treatment of the @entity5 with reservation of the ovary should be further investigated.

title: [Ovarian @entity3 in uterine XXXX : analysis of 17 cases].

entities_list: @entity43 :: ('MESH:D010051', 'Disease') :: ['ovarian metastasis']

entities_list: @entity1 :: ('9606', 'Species') :: ['Patients', 'patients']

entities_list: @entity5 :: ('MESH:D009369', 'Disease') :: ['cervical cancer']

entities_list: @entity957 :: ('MESH:D002294', 'Disease') :: ['squamous cell carcinoma']

entities_list: @entity3 :: ('MESH:D009362', 'Disease') :: ['metastasis']

entities_list: @entity420 :: ('MESH:D000230', 'Disease') :: ['adenocarcinoma']

answer: @entity5 :: (MESH:D009369,Disease) :: ['cervical cancer']


abstract: OBJECTIVES: Purpose of this study is to examine the relationship between the magnetic resonance imaging (MRI) findings, @entity158 scores, and opiates use in @entity1 with @entity2649 ( @entity2649 ) undergoing lumbar epidural @entity134 (LES) injections by retrospective review of 719 @entity1 ' electronic medical records. METHODS: Reviewed were Visual Analog Scale (VAS) @entity158 scores and opioid use before and 8 to 12 weeks after series of LES injections. The @entity850 @entity158 index (SPI) was produced by adding an assigned numerical value of severity (1=mild, 2=moderate, 3=severe) to the number of lumbar vertebral levels affected by @entity2649 on MRI (lateral or central). RESULTS: The average age of @entity1 was 68.4 years. There was no relationship between the pretreatment age, sex, or number of vertebral levels affected on MRI with pretreatment @entity227 scores or opioid use. The degree of @entity2649 present on MRI, categorized as a mild, moderate, or severe, correlated clearly with initial @entity227 scores (P=0.017). The improvement in @entity227 scores after LES injections correlated well with number of levels affected (P=0.003) and the severity of @entity850 (P=0.12). Positive correlation was observed between change in @entity227 score 8 to 12 weeks after the series of LES injections and the SPI (P=0.001). There were no differences found in opioid use. DISCUSSION: The improvement in @entity227 scores after LES injections correlated well with the changes in the SPI except in those @entity1 classified on MRI as severe @entity2649 and more than 3 lumbar levels affected. That @entity1 group is unlikely to benefit from LES injections.

title: Value of the magnetic resonance imaging in @entity1 with @entity158 ( XXXX ) undergoing lumbar epidural @entity134 injections.

entities_list: @entity2649 :: ('MESH:C563613', 'Disease') :: ['LSS', 'lumbar spinal stenosis']

entities_list: @entity134 :: ('CHEBI:35341', 'Chemical') :: ['steroid']

entities_list: @entity850 :: ('MESH:D003251', 'Disease') :: ['stenosis']

answer: @entity2649 :: (MESH:C563613,Disease) :: ['LSS']


abstract: PURPOSE: To test the hypothesis that consolidation therapy with yttrium-90 ((90)Y) -ibritumomab tiuxetan after brief initial therapy with four cycles of rituximab plus @entity786 , @entity632 , @entity1891 , and @entity229 (R- @entity3726 ) in @entity1 with previously untreated @entity1073 would be a well-tolerated regimen that would improve outcomes compared with historical R- @entity3726 data. @entity1 AND METHODS: @entity1 >=  18 years old with histologically confirmed @entity1073 expressing @entity2225 and @entity4910 who had not received any previous therapy and had an Eastern Cooperative Oncology Group performance status of 0 to 2 and adequate organ function were eligible. The study enrolled and treated 57 @entity1 , of whom 56 @entity1 were eligible. Fifty-two @entity1 (50 eligible @entity1 ) received (90)Y-ibritumomab tiuxetan. The study design required 52 eligible @entity1 to detect a 50% improvement in the median time to treatment failure (TTF) compared with that reported for six cycles of R- @entity3726 . RESULTS: With 56 analyzed @entity1 (median age, 60 years; @entity1 , 73%), the overall response rate was 82% (55% complete response/complete response-unconfirmed). With a median follow-up of 72 months, the median TTF was 34.2 months. The median overall survival (OS) has not been reached, with an estimated 5-year OS of 73% (79% for @entity1  <= age 65 years v 62% for @entity1 > age 65 years; P = .08 [log-rank test]). There were no unexpected @entity137 . CONCLUSION: R- @entity3726 given for four cycles followed by (90)Y-ibritumomab tiuxetan compared favorably with historical results with six cycles of R- @entity3726 in @entity1 with previously untreated @entity1073 . This regimen was well tolerated and should be applicable to most @entity1 with this disease.

title: Phase II study of rituximab plus @entity786 , @entity632 , @entity1891 , and @entity229 immunochemotherapy followed by yttrium-90-ibritumomab tiuxetan in untreated XXXX : Eastern Cooperative Oncology Group Study E1499.

entities_list: @entity632 :: ('MESH:D004317', 'Chemical') :: ['doxorubicin']

entities_list: @entity1 :: ('9606', 'Species') :: ['Patients', 'patients', 'PATIENTS', 'men']

entities_list: @entity137 :: ('MESH:D064420', 'Disease') :: ['toxicities']

entities_list: @entity229 :: ('MESH:D011241', 'Chemical') :: ['prednisone']

entities_list: @entity786 :: ('MESH:D003520', 'Chemical') :: ['cyclophosphamide']

entities_list: @entity1891 :: ('MESH:D014750', 'Chemical') :: ['vincristine']

entities_list: @entity1073 :: ('MESH:D020522', 'Disease') :: ['mantle-cell lymphoma']

answer: @entity1073 :: (MESH:D020522,Disease) :: ['mantle-cell lymphoma']


abstract: OBJECTIVE: Ventilation/perfusion pulmonary scintigraphy (PS), the current mainspring in the diagnosis of @entity4 ( @entity4 ), is frequently non-conclusive. The objective of this study was to determine, prospectively, the diagnostic value of the association of D-dimers and @entity1514 ( @entity1514 ) in a continuous series of ambulatory adults with suspected @entity4 and admitted to a cardiologic emergency unit. METHODS: Exclusion criteria were as follows: symptoms or clinical signs of seventy, contraindication for @entity1514 and/or on pulmonary angiography, curative anticoagulant therapy for more than 48 hours, history of @entity4 less than 3 months before or the impossibility of conducting all the examinations with 48 hours. All the @entity1 underwent determination of D-dimers by rapid ELISA test, @entity1514 and 2 reference examinations, venous Doppler of the lower limbs and a PS, completed by pulmonary angiography if the PS did not permit diagnosis and the venous Doppler was negative. RESULTS: One hundred and six @entity1 were selected over a recruitment period of 18 months. The prevalence of @entity4 was of 45% (48/106). Forty-four of the 48 @entity4 of the series were central form. @entity1514 was considered dubious in 10 @entity1 (10.4%, @entity4 + n = 2, @entity4 - n = 8). The results of D-dimers were negative in only 34.5% @entity1 without @entity4 (20/58). Pulmonary angiography was necessary in 15 @entity1 . The negative and positive predictive values of D-dimers were respectively of 100 and 55.8% (48/86) and those of @entity1514 respectively 100 (46/46) and 92% (46/50). CONCLUSION: The diagnostic strategy of clinical suspicion of @entity4 , starting with determination of D-dimers by rapid ELISA test followed by @entity1514 in the case of a positive result, was particularly effective in this series of @entity1 with a high prevalence of @entity4 . These results must be confirmed in a larger series and in a general emergency unit.

title: [Association of D-dimer and @entity1514 for diagnosis of pulmonary embolism. Prospective study of 106 ambulatory XXXX ].

entities_list: @entity1 :: ('9606', 'Species') :: ['patients']

entities_list: @entity4 :: ('MESH:D004487', 'Disease') :: ['PE', 'pulmonary oedema']

entities_list: @entity1514 :: ('MESH:D013896', 'Disease') :: ['helicoidal thoracic scanner', 'HTS']

answer: @entity1 :: (9606,Species) :: ['patients']


abstract: The survival rates in childhood @entity981 ( @entity981 ) have improved dramatically; however, @entity1 still suffer from a variety of drug-related @entity137 . Individualized therapy regimens promise the least toxic therapy regimen with the best hematologic outcome. Our aim was to investigate whether increased individual glucocorticoid sensitivity due to the @entity16123 polymorphism of the @entity4738 increased susceptibility to @entity134 -related @entity137 during @entity981 therapy. A total of 346 @entity981 @entity1 were involved in the present study. @entity16123 carrier status was investigated by allele-specific PCR. Clinical and laboratory signs of glucocorticoid-related @entity137 , Day 8 @entity229 response, and 5-year event-free survival were analyzed and compared retrospectively. Thirty-two of the 346 @entity1 were heterozygous carriers (9.2 %). Hepatotoxicity (31.3 vs. 11.2 %, p = 0.004, carriers and non-carriers, respectively) and @entity413 metabolism abnormalities (18.8 vs. 3.8 %, p = 0.001, carriers and non-carriers, respectively) were significantly more frequent among carriers. There was no difference in the incidence of @entity101 and @entity75 / @entity716 among carriers and non-carriers. Carriers were also more prone to have a combination of @entity137 . All 363S carriers were good @entity229 responders (100 %) and had significantly better 5-year event-free survival rates (93.1 vs. 71.86 %, p = 0.012), whereas among non-carriers there were more poor @entity229 responders (8.28 %) and worse 5-year event-free survival rates. @entity1 with the @entity16123 polymorphism in the @entity4738 are more prone to @entity134 -related @entity137 during @entity981 therapy and should be monitored more closely. @entity1 with @entity16123 polymorphism of the @entity4738 may be appropriate candidates for inclusion in the design of individualized therapies.

title: The @entity4738 gene polymorphism XXXX predisposes to more severe toxic side effects during pediatric @entity981 ( @entity981 ) therapy.

entities_list: @entity1 :: ('9606', 'Species') :: ['Patients', 'patients']

entities_list: @entity981 :: ('MESH:D054198', 'Disease') :: ['pediatric ALL', 'ALL', 'acute lymphoid leukemia']

entities_list: @entity4738 :: ('2908', 'Gene') :: ['glucocorticoid receptor']

entities_list: @entity137 :: ('MESH:D064420', 'Disease') :: ['toxicity', 'toxicities']

entities_list: @entity101 :: ('MESH:D006973', 'Disease') :: ['hypertension']

entities_list: @entity75 :: ('MESH:D001927', 'Disease') :: ['encephalopathy']

entities_list: @entity716 :: ('MESH:D011605', 'Disease') :: ['psychosis']

entities_list: @entity413 :: ('MESH:D005947', 'Chemical') :: ['glucose']

answer: @entity16123 :: (p|SUB|N|363|S,ProteinMutation) :: ['N363S']


abstract: This study was designed to determine the effects of @entity53 (E2) in overcoming the cardiac over-loading and @entity299 in @entity35 . E2 (100 ng/kg) or oil was applied in female @entity35 with or without bilateral ovariectomy and with or without @entity1498 of the abdominal aorta after 4 or 8 days. By post-operative day 4, the heart weight, the left ventricular weight, the latent form of @entity11017 in @entity35 hearts with or without the ovary intact had significantly increased while these changes were reversed after E2 treatment. Although animals with the ovaries intact overcame the @entity1184 effects and the consumption of @entity11017 , these effects were not restored in ovariectomized animals in which more @entity82 could be found by day 8. Among the @entity2135 signaling, the levels of @entity2135 , the activities of PI3K- @entity2308 for cardiomyocyte survival, and MEK-ERKs for non-cardiomyocyte proliferation pathways had significantly increased by day 4. These increasing trends were enhanced by E2 treatment. However, down-regulation was only observed on day 8 in ovariectomized animals. Similarly, elevated expressions of the steady-state mRNA of @entity2135 , IGF-IR, and Cox vb were observed on day 4 in animals with the ovaries intact and these expressions were enhanced by E2 treatment. In contrast, down-regulation on day 8 in ovariectomized animals was not enhanced by E2. The calcineurin/NFAT-3 pathway was suppressed on day 4 but was elevated on day 8 in ovariectomized animals. These findings indicate that signaling pathways may be plausible mechanisms for the cardiac protective effects of E2 administration.

title: @entity53 reduces cardiac hypertrophy mediated through the up-regulation of PI3K/ XXXX and the suppression of calcineurin/NF-AT3 signaling pathways in @entity35 .

entities_list: @entity82 :: ('MESH:D005355', 'Disease') :: ['fibrosis']

entities_list: @entity1184 :: ('MESH:D006984', 'Disease') :: ['hypertrophic']

entities_list: @entity53 :: ('MESH:D004958', 'Chemical') :: ['17beta-estradiol']

entities_list: @entity1498 :: ('MESH:D001017', 'Disease') :: ['coarctation']

entities_list: @entity299 :: ('MESH:D006331', 'Disease') :: ['cardiac fibrosis']

entities_list: @entity35 :: ('10116', 'Species') :: ['rat', 'Sprague-Dawley rats', 'rats']

answer: @entity2308 :: (24185(Tax:10116),Gene) :: ['Akt']


abstract: The aim of this study is to analyze different reflux-patterns by 24-hour ambulatory pH-metry and to correlate them with clinical symptoms and intensity of @entity2910 . 115 @entity1 (50 males/65 females) with a median age of 47 +/- 16 years, typical @entity304 have been studied and classified attending to the grade of @entity2910 microscopically only 17 cases and endoscopically (grade I = 29, grade II = 44 and grade III/IV = 25 @entity1 ). Demeester's score has been used for clinical evaluation. Ambulatory pH-metry has been done with a Holter Synectics Digitrapper @entity15617 , which registered intraesophageal pH-variations every 4 seconds during 24 hours. 28 normal subjects (13 males/15 females) with a median age of 51 +/- 16 years are referred as the control group. Clinical symptoms became more intensified when pH-metric alterations resulted more evident. @entity158 was noted in 12 from 115 @entity1 , increasing its frequency in parallel fashion to that of the degree of @entity2910 (6% in grade 0, 9% in grades I/II and 20% in grades II/IV). With increasing grades of @entity2910 all parameters departed from normality, with significant differences between median values of the different parameters (to the exception of @entity2749 ) when comparing @entity1 with low-grade @entity2910 (O/I) and high-grade @entity2910 (II/III/IV). There is an excellent correlation between severity of @entity2910 and % of time to acid exposure (Spearman's correlation coefficient). Only 5% of the @entity1 with @entity2910 presented normal pH-metry values and corresponded to @entity2910 grade O/I. No @entity1 had only a night reflux pattern, but 10% of our @entity1 had only a day reflux pattern, the mixed pattern being the most frequent one (85%). The fact that 82% of our @entity1 with microscopical @entity2910 had a pathological pH-metry recommends the use this method in @entity1 with clinical @entity304 and with normal endoscopy.

title: [Value of long-term ambulatory pH-metry in the assessment of XXXX with reflux esophagitis].

entities_list: @entity1 :: ('9606', 'Species') :: ['patients', 'patient']

entities_list: @entity2749 :: ('MESH:C580065', 'Disease') :: ['reflux episodes']

entities_list: @entity304 :: ('MESH:D010302', 'Disease') :: ['reflux symptoms']

entities_list: @entity2910 :: ('MESH:D004941', 'Disease') :: ['esophagitis']

entities_list: @entity158 :: ('MESH:D010146', 'Disease') :: ['Thoracic pain']

answer: @entity1 :: (9606,Species) :: ['patients']


abstract: PURPOSE: The aim of this study was to assess the construct validity and clinical application of the Pediatric Sleep Survey Instrument (PSSI) as a tool to screen for @entity25 @entity1353 (SDB) in @entity1 . METHODS: Polysomnography (PSG) outcomes and PSSI subscale scores were compared between a clinical cohort (N   =   87, 5-10 years, 62 M/25 F) and a nonsnoring community sample (N   =   55, 5-10 years, 28 M/27 F). Group comparisons assessed the ability of the PSSI subscales to discriminate between the clinical and community cohorts. Receiver operating characteristic (ROC) curves assessed construct validity, with the @entity386 / @entity387 Index (AHI) >5 events/h, OSA-18 score >60, and Pediatric Daytime Sleepiness Scale (PDSS) above the 70th percentile as the target references. RESULTS: The clinical group had more respiratory events, respiratory-related arousals, @entity1949 , and lower @entity26 saturation nadir than the community group (p   <   0.001 for all). PSSI subscale scores of Morning Tiredness, Night Arousals, SDB, and Restless Sleep were higher (p   <   0.001 for all) in the clinical cohort, confirming the tool's ability to identify clinically relevant sleep problems. ROC curves confirmed the diagnostic accuracy of the SDB subscale against an AHI   >   5 events/h (area under the curve (AUC)   =   0.7), an OSA-18 score >60 (AUC   =   0.7), and a PDSS score in the 70th percentile (AUC   =   0.8). The Morning Tiredness subscale accurately predicted a PDSS score in the 70th percentile (AUC   =   0.8). A cutoff score of 5 on the SDB subscale showed a sensitivity of 0.94 and a specificity of 0.76, correctly identifying 77 and 100 % of the clinical and community cohorts, respectively. CONCLUSION: The PSSI Sleep @entity387 subscale is a valid tool for screening SDB and @entity25 in @entity1 aged 5-10 years.

title: Pediatric Sleep Survey Instrument--a screening tool for @entity25 XXXX .

entities_list: @entity1 :: ('9606', 'Species') :: ['children']

entities_list: @entity1949 :: ('MESH:D012892', 'Disease') :: ['fragmented sleep']

entities_list: @entity387 :: ('MESH:D012891', 'Disease') :: ['Disordered Breathing', 'Hypopnea']

entities_list: @entity1353 :: ('MESH:D004417', 'Disease') :: ['breathing']

entities_list: @entity26 :: ('MESH:D010100', 'Chemical') :: ['oxygen']

entities_list: @entity25 :: ('MESH:D012893', 'Disease') :: ['sleep disordered', 'daytime sleepiness']

answer: @entity1353 :: (MESH:D004417,Disease) :: ['breathing']


abstract: Succinylated mercerized cellulose ( @entity27447 ) was used to synthesize an anion exchange resin. @entity27447 , containing @entity4880 groups was reacted with @entity31000 to introduce @entity6115 functionality to this material to obtain @entity27447 . @entity27447 was reacted with @entity11906 to quaternize the @entity6115 groups from this material to obtain @entity27447 . Cells 2 and 3 were characterized by mass percent gain, degree of amination and quaternization, FTIR and @entity12289 . Cells 2 and 3 showed degrees of amination and quaternization of 2.8 and 0.9 mmol/g and @entity1568 content of 6.07% and 2.13%, respectively. @entity27447 was used for @entity6596 adsorption studies. Adsorption equilibrium time and optimum pH for @entity6596 adsorption were found to be 300 min and 3.1, respectively. The Langmuir isotherm was used to model adsorption equilibrium data. The adsorption capacity of @entity27447 was found to be 0.829 mmol/g. Kinetic studies showed that the rate of adsorption of @entity6596 on @entity27447 obeyed a pseudo-second-order kinetic model.

title: Adsorption of XXXX ion from aqueous solution by succinylated mercerized cellulose functionalized with quaternary ammonium groups.

entities_list: @entity1568 :: ('MESH:D009584', 'Chemical') :: ['nitrogen']

entities_list: @entity4880 :: ('CHEBI:33575', 'Chemical') :: ['carboxylic acid']

entities_list: @entity31000 :: ('MESH:D014266', 'Chemical') :: ['triethylenetetramine']

entities_list: @entity11906 :: ('MESH:C014055', 'Chemical') :: ['methyl-iodide']

answer: @entity6596 :: (MESH:C074702,Chemical) :: ['chromium (VI)']


abstract: To elucidate the reasons why mRNA expression of the @entity30938 candidate tumor-suppressor gene was severely reduced in the @entity11 -derived cell line H4, as demonstrated in a previous study, we performed a cytogenetic analysis of this cell line using conventional methods and fluorescence in situ hybridization (FISH) techniques [spectral karyotyping (SKY), interphase- and chromosome FISH of metaphases (I- and C-FISH)]. Cell line H4 is monoclonal and near triploid (+/-3n). SKY enabled us to detect 24 structural aberrations: unbalanced translocations, n = 12; deletions, n = 10; insertion, n = 1; duplication, n = 1. The results were confirmed by I- and C-FISH analysis using chromosome-specific paints, centromer-specific probes and locus-specific probes for @entity876 , @entity983 / @entity983 , @entity30938 , @entity4910 , @entity5738 , @entity9604 / @entity9604 , @entity5316 , and the genomic region 13q14.3 containing the Rb locus. We found loss of one copy of @entity876 as well as of one copy of Rb. Complete loss of @entity983 / @entity983 was detected, while all copies of @entity30938 and @entity4910 were preserved. Interestingly, there was a gain of @entity9604 / @entity9604 and @entity5738 , which were each present in quadruplicate. Additionally, the @entity5316 locus revealed mosaicism of cells with three and four copies, respectively. Additionally, a 5q-chromosome [del(5)(q13q33)] was found, which is one of the common features in @entity1583 , and der(12)t(1;12) was found, suggesting that there might be an additional @entity9604 / @entity9604 fusion protein. The combination of SKY, I- and C-FISH demonstrates that the @entity1358 harbors cytogenetic aberrations that are reported to occur in @entity11 -derived cell lines and additional chromosomal aberrations that have so far not been reported to occur in these cell lines. The complex aberrant karyotype and possibly generation of transcription factors by fusion proteins might be reasons for the impaired mRNA expression of the @entity30938 candidate tumor-suppressor gene in cell line H4.

title: Identification of uncommon chromosomal aberrations in the XXXX by spectral karyotyping.

entities_list: @entity1358 :: ('MESH:D002292', 'Disease') :: ['neuroglioma cell line H4']

entities_list: @entity1583 :: ('MESH:D019337', 'Disease') :: ['hematological malignancies']

answer: @entity1358 :: (MESH:D002292,Disease) :: ['neuroglioma cell line H4']


abstract: BACKGROUND _ AIMS: @entity7318 and insulin-like growth factor I ( @entity7424 ) stimulate small bowel growth. The aim of this study was to analyze whether @entity7424 mediates enterotrophic actions of @entity7318 . METHODS: @entity7424 @entity19 that overexpress an @entity7424 transgene driven by the @entity19 metallothionein I promoter and are @entity7318 deficient were compared with wild-type littermates. Growth of small bowel, abundance and localization of messenger RNAs for the @entity10246 were assayed. RESULTS: Small bowel length and mass were greater in @entity7424 @entity19 than in wild-type @entity19 . Villus height, crypt depth, and crypt cell mitoses were greater in jejunum of transgenics than wild-type @entity19 , but jejunal disacharidase activities were not increased. The transgene was expressed strongly in villus epithelial cells. @entity10246 messenger RNA was localized in the lamina propria. Regional expression of both correlated with the increase in mucosal mass. CONCLUSIONS: Effects of @entity7424 overexpression on intestinal length and mucosal mass were similar to effects of @entity7318 overexpression observed previously. Excess of @entity7424 increased crypt cell proliferation, whereas excess of @entity7318 did not increase crypt cell proliferation. @entity7424 excess stimulated differentiation of intestinal epithelial cells less effectively than @entity7318 excess.

title: Enhanced growth of small bowel in XXXX expressing human insulin-like growth factor I.

entities_list: @entity19 :: ('10090', 'Species') :: ['mice', 'mouse', 'transgenic mice']

entities_list: @entity7318 :: ('14599(Tax:10090)', 'Gene') :: ['growth hormone', 'Growth hormone']

entities_list: @entity10246 :: ('16009(Tax:10090)', 'Gene') :: ['IGF-I transgene, and insulin-like growth factor-binding protein 3', 'Insulin-like growth factor-binding protein 3']

answer: @entity19 :: (10090,Species) :: ['transgenic mice']


abstract: New immunosuppressive agents and regimens should be evaluated specifically in living donor liver transplant @entity1 due to potential clinical and pharmacokinetic differences between deceased donor and living donor transplant recipients. The analysis presented here is the first direct comparison of clinical outcomes using @entity205 microemulsion (CsA-ME) with monitoring of blood concentration at 2 hours postdose (C2) and @entity1140 -based immunosuppression in living donor liver transplantation. The analysis was conducted on the data provided by the 39 recipients of a living donor transplant out of the 495 @entity1 enrolled in a 6-month, randomized, prospective, multicenter, open-label study (LIS2T). @entity1 were randomized to CsA-ME (C2 monitoring) or @entity1140 (monitoring of predose trough drug blood level [C0)]) and were administered corticosteroids with or without @entity500 . Twenty-three living-donor @entity1 received CsA-ME and 16 received @entity1140 . By month 6, 9% of @entity1 receiving CsA-ME and 19% of those receiving @entity1140 had lost their graft or died (not significant [NS]). Nine episodes of biopsy-proven acute rejection were reported: 4 in the CsA-ME group (17%) and 5 in the @entity1140 cohort (31%, NS). There were no significant differences in any safety parameter between groups. The most frequently reported serious adverse events were @entity281 , which occurred in 14 @entity1 in the CsA-ME group (61%) and 13 @entity1 in the @entity1140 arm (81%, NS). Twelve @entity1 in the CsA-ME arm (52%) and 5 in the @entity1140 arm (31%, NS) discontinued the study prematurely. In conclusion, CsA-ME C2 monitoring or @entity1140 both offer effective protection against rejection in living donor liver transplants while maintaining a good safety profile.

title: Comparison of @entity205 microemulsion and XXXX in 39 recipients of living donor liver transplantation.

entities_list: @entity1 :: ('9606', 'Species') :: ['Patients', 'patients']

entities_list: @entity500 :: ('MESH:D001379', 'Chemical') :: ['azathioprine']

entities_list: @entity205 :: ('MESH:D016572', 'Chemical') :: ['cyclosporine']

entities_list: @entity281 :: ('MESH:D007239', 'Disease') :: ['infections']

entities_list: @entity1140 :: ('MESH:D016559', 'Chemical') :: ['tacrolimus']

answer: @entity1140 :: (MESH:D016559,Chemical) :: ['tacrolimus']


abstract: PURPOSE: To describe the results of a series of 63 Western @entity1 presenting with @entity356 and treated with surgery and intraoperative radiation therapy (IORT) over a 8-year period and to discuss the role of IORT when combined with limited lymph node dissection. METHODS AND MATERIALS: From 1986 to 1993, 63 @entity1 with @entity356 have been operated in the department of radiation oncology of the Hospices Civils de Lyon. The stage was: I in 17, II in 11, IIIA in 9, IIIB in 20, and IV in 6. The lymph node dissection was considered to be limited in 56 @entity1 and extended in 7. The IORT dose ranged from 12 to 23 Gy (median: 15). Thirty @entity1 also underwent a postoperative external beam irradiation with a standard dose of 44-46 Gy. RESULTS: The postoperative mortality rate was 4.8%. The 5-year overall survival in the entire series was 47% and was 82, 55, 78, 20, and 0% in Stages I, II, IIIA, IIIB, and IV, respectively. Loco-regional relapse occurred in 15 of 63 @entity1 and @entity3 in 15 of 63. CONCLUSION: In Western @entity1 treated by gastrectomy for @entity420 , IORT combined with limited lymph node dissection may provide overall survival similar to that observed after gastrectomy with extended lymph node dissection but with less postoperative mortality.

title: Intraoperative radiation therapy combined with limited lymph node resection in XXXX : an alternative to extended dissection?

entities_list: @entity1 :: ('9606', 'Species') :: ['patients']

entities_list: @entity420 :: ('MESH:D000230', 'Disease') :: ['adenocarcinoma of the stomach']

entities_list: @entity356 :: ('MESH:D013274', 'Disease') :: ['gastric adenocarcinoma']

entities_list: @entity3 :: ('MESH:D009362', 'Disease') :: ['metastases']

answer: @entity356 :: (MESH:D013274,Disease) :: ['gastric cancer']


abstract: PURPOSE: The present study using the Dunning R3327-PAP @entity35 @entity263 model was designed to study the effect on @entity5 growth of castration prior to or after irradiation with 20-25 Gy as compared with either irradiation or castration alone. METHODS AND MATERIALS: @entity35 were bilaterally orchidectomized. During the irradiation procedure the nonanesthetized animals were held in a metallic frame with a strong @entity2708 net and they were observed by means of a video camera. The suboptimal irradiation dose was given once daily with a 4-MeV linear accelerator, 4-5 Gy/fraction, during 5 consecutive days. @entity5 volumes and @entity35 weights were followed. At the end point of the study the animals were sacrificed and the @entity5 were morphometrically analyzed. RESULTS: The combination of irradiation and castration delayed @entity5 regrowth better than irradiation alone with the same suboptimal dose. Castration before irradiation delayed @entity5 regrowth more efficiently than castration after irradiation. However, castration alone delayed @entity5 regrowth even more effectively than suboptimal irradiation doses combined with castration. CONCLUSIONS: In combination with suboptimal irradiation neoadjuvant @entity342 deprivation was more inhibitory to @entity35 @entity263 regrowth than adjuvant @entity342 deprivation. Irradiation with suboptimal doses combined with castration may cause an earlier relapse to @entity342 -independent @entity5 growth than castration alone.

title: Combined castration and fractionated radiotherapy in an experimental XXXX .

entities_list: @entity263 :: ('MESH:D011471', 'Disease') :: ['prostatic adenocarcinoma']

entities_list: @entity5 :: ('MESH:D009369', 'Disease') :: ['tumor', 'Tumor', 'tumors']

entities_list: @entity342 :: ('CHEBI:50113', 'Chemical') :: ['androgen']

answer: @entity263 :: (MESH:D011471,Disease) :: ['prostatic adenocarcinoma']


abstract: BACKGROUND: Research on @entity1005 ( @entity1005 ) has focused primarily on Vietnam War veterans. A handful of recent studies have been conducted on samples of the general population. OBJECTIVE: We sought to examine gender differences in exposure to traumatic events and in the emergence of @entity1005 following exposure in the general population. SUBJECTS: A representative sample of 2181 @entity1 in the Detroit metropolitan area, ages 18-45 years. METHODS: Subjects were interviewed to assess history of traumatic events and @entity1005 using Diagnostic and Statistical Manual of @entity146 (Fourth Edition) criteria. The risk of @entity1005 was assessed in relation to a representative sample of @entity130 experienced in the population. RESULTS: Lifetime prevalence of traumatic events was slightly higher in @entity1 than in @entity1 . The risk for @entity1005 following traumatic experiences was twofold higher in @entity1 than in @entity1 . This gender difference was primarily due to @entity1 's greater risk of @entity1005 following events that involved assaultive violence. The probability of @entity1005 in @entity1 versus @entity1 exposed to assaultive violence was 36% versus 6%. Prior exposure to assaultive violence was associated with an increased risk of @entity1005 from a subsequent @entity130 ; the gender difference in the vulnerability for @entity1005 is not explained by prior exposure. Duration of @entity1005 was longer in @entity1 than in @entity1 . CONCLUSION: The burden of @entity1005 in U.S. communities is greater in @entity1 than in @entity1 , chiefly due to the greater effect of assaultive violence on @entity1 .

title: Gender differences in @entity130 and XXXX .

entities_list: @entity1 :: ('9606', 'Species') :: ['women', 'persons', 'men']

entities_list: @entity130 :: ('MESH:D014947', 'Disease') :: ['traumas', 'trauma']

entities_list: @entity1005 :: ('MESH:D013313', 'Disease') :: ['posttraumatic stress disorder', 'PTSD']

entities_list: @entity146 :: ('MESH:D001523', 'Disease') :: ['Mental Disorders']

answer: @entity1005 :: (MESH:D013313,Disease) :: ['posttraumatic stress disorder']


abstract: A 29-yr-old white @entity1 presented with chronic @entity55 in the left lower lobe and with left @entity1143 . She was known to have @entity29 , but she was asymptomatic under maintenance treatment with @entity3504 . She received numerous antibiotic regimens according to susceptibility testing of microorganisms cultured from sputum and bronchial lavage and on an empiric basis was also given antituberculosis treatment, but there was no clinical improvement or change in the chest radiographic findings. Sputum was repeatedly examined and yielded, among other organisms, Clostridium inocuum, Enterobacter, @entity3274 , @entity5609 , and @entity794 . On one microscopic examination of sputum, the presence of feculent material was suspected. A subsequent gastrografin enema revealed a cologastric and colobronchial fistula between the splenic flexture of the colon and the greater curve of the stomach and the bronchial system. Segmental resection of the colon and resection of the lower lobe of the left lung were performed. Histologic findings of the resected colon were consistent with @entity30 . After a long period of postoperative recovery, the @entity1 returned to good general health and well-being. To our knowledge, a colobronchial fistula caused by @entity30 has not been previously reported.

title: Colobronchial fistula: a rare complication of XXXX .

entities_list: @entity1 :: ('9606', 'Species') :: ['woman', 'patient']

entities_list: @entity1143 :: ('MESH:D010996', 'Disease') :: ['pleural effusion']

entities_list: @entity55 :: ('MESH:D011014', 'Disease') :: ['pneumonia']

entities_list: @entity5609 :: ('584', 'Species') :: ['Proteus mirabilis']

entities_list: @entity794 :: ('1280', 'Species') :: ['Staphylococcus aureus']

entities_list: @entity29 :: ('MESH:D015212', 'Disease') :: ['inflammatory bowel disease']

entities_list: @entity3274 :: ('573', 'Species') :: ['Klebsiella pneumoniae']

entities_list: @entity30 :: ('MESH:D003424', 'Disease') :: ["Crohn's colitis", "Crohn's disease"]

answer: @entity30 :: (MESH:D003424,Disease) :: ['Crohn's colitis']


abstract: AIMS: The aim of this study was to establish the cytokeratin expression profile of different types of @entity259 . MATERIALS AND METHODS: The expression of cytokeratins (CKs) 1, 4, 6, 7, 10/13, 18, 19 and 20 in 153 @entity259 were examined by immunohistochemistry. RESULTS: All @entity1377 (n=86) and @entity189 (n=19) showed expression of @entity5822 and @entity2873 . The staining was often diffuse. @entity4166 staining was expressed in all @entity1377 and the staining was often diffuse. The staining was noted in 68% of @entity189 and the staining was often focal. No difference in the expression was noted between the minimally invasive and widely invasive @entity189 . Poorly differentiated @entity189 (n=10) showed @entity5822 , @entity2873 , @entity4166 expression in 60%, 60% and 40%, respectively. @entity189 (n=25) expressed @entity5822 in 84%, @entity2873 in 80%, @entity4166 in 76% and @entity7434 /13 in 16%. @entity189 (n=13) showed @entity5822 expression in 100%, @entity2873 in 85% and @entity4166 in 77%. None of the @entity189 showed diffuse positivity to @entity4166 . All the @entity259 were negative for @entity54155 . CONCLUSIONS: Cytokeratin expression profile for each @entity259 was established.

title: Cytokeratin expression profiles in XXXX .

entities_list: @entity1377 :: ('MESH:D002291', 'Disease') :: ['papillary carcinomas']

entities_list: @entity189 :: ('MESH:D002277', 'Disease') :: ['carcinomas', 'Anaplastic carcinomas', 'follicular carcinomas', 'Medullary carcinomas', 'medullary carcinomas']

entities_list: @entity259 :: ('MESH:D013964', 'Disease') :: ['type of thyroid carcinoma', 'thyroid carcinomas', 'thyroid carcinoma']

answer: @entity259 :: (MESH:D013964,Disease) :: ['thyroid carcinomas']


abstract: Existing @entity5176 are known to target the type II topoisomerases in bacteria. In order to determine which of these targets are of key importance in @entity328 treated with @entity28442 ( @entity53222 ), a novel des-F(6) @entity1536 , resistant mutants were selected in several steps of increasing resistance by plating pneumococci on a series of blood agar plates containing serial twofold-increasing concentrations of drug. After incubation, colonies that arose were selected and passaged twice on antibiotic-containing media at the selection level. Mutants generally showed increases in resistance of four- to eightfold over the prior level of susceptibility. Mutants in the next-higher level of resistance were selected from the previous round of resistant mutants. Subsequently, chromosomal DNA was prepared from parental (R6) pneumococci and from at least three clones from each of four levels of increasing antibiotic resistance. Using PCR primers, 500- to 700-bp amplicons surrounding the @entity1536 resistance determining regions (QRDR) of gyrA, gyrB, parC, and parE genes were prepared from each strain. Internal primers were used to sequence both DNA strands in the regions of approximately 400 bp centered on the QRDR. Mutations identified with increasing levels of resistance included changes in GyrA at Ser-81 and @entity367 -85 and changes in ParC at Ser-79 and @entity2574 -83. Changes in GyrB and ParE were not observed at the levels of resistance obtained in this selection. The resistance to comparator @entity5176 ( @entity800 , @entity2177 , and @entity3477 ) also increased in four- to eightfold steps with these mutations. The intrinsically greater level of antibacterial activity and thus lower MICs of @entity28442 observed at all resistance levels in this study may translate to coverage of these resistant pneumococcal strains in the clinic.

title: Selection and genetic characterization of @entity328 mutants resistant to the des-F(6) XXXX @entity28442 .

entities_list: @entity3477 :: ('MESH:C104727', 'Chemical') :: ['moxifloxacin']

entities_list: @entity5176 :: ('MESH:D015363', 'Chemical') :: ['quinolones']

entities_list: @entity2177 :: ('MESH:D002939', 'Chemical') :: ['ciprofloxacin']

entities_list: @entity800 :: ('MESH:D015242', 'Chemical') :: ['levofloxacin']

entities_list: @entity328 :: ('1313', 'Species') :: ['Streptococcus pneumoniae']

entities_list: @entity1536 :: ('CHEBI:23765', 'Chemical') :: ['quinolone']

answer: @entity1536 :: (CHEBI:23765,Chemical) :: ['quinolone']


abstract: BACKGROUND: The clinical syndrome of @entity991 ( @entity991 ), diagnosed in about 5% of @entity1 with @entity31 ( @entity31 ), has been shown to be associated with @entity5042 after ileal pouch-anal @entity254 . The aim of this study was to ascertain whether @entity31 @entity1 with @entity255 on liver biopsy at proctocolectomy, with or without the clinical syndrome of @entity991 , have an increased risk of inflammatory changes in the ileal reservoir mucosa and clinical @entity5042 . METHODS: Of the consecutive 81 @entity31 @entity1 treated with restorative proctocolectomy with ileal J reservoir at Tampere University Hospital between 1985 and 1991, 73 with peroperative liver biopsy were included. A peroperative liver biopsy was obtained during proctocolectomy. After a median follow up of 64 months, pouch biopsy specimens were obtained. Periods of clinical @entity5042 were diagnosed by means of clinical criteria alone or by clinical criteria combined with the results of previous pouch endoscopies in all @entity1 . RESULTS: Ten @entity1 (14%) showed histologic features consistent with small-duct @entity991 on liver biopsy. Endoscopic retrograde cholangiography had previously been performed on four of these @entity1 , and all four had large-duct @entity991 . @entity1 with @entity255 had significantly more severe chronic, but not acute, @entity32 in the pouch mucosa than @entity1 without @entity255 . At least one episode of @entity5042 occurred in 30% of the @entity1 without @entity255 as compared with 90% of the @entity1 with @entity255 . @entity5042 was more frequent in the group with @entity255 than in the group without it (70% versus 11%). CONCLUSIONS: The only means of detecting all @entity31 @entity1 with @entity255 is a liver biopsy. @entity255 , either with the clinical syndrome of @entity991 or found on liver biopsy, seems to be a risk factor for chronic-type inflammatory changes in the pouch mucosa and for the development of @entity5042 .

title: Chronic inflammatory changes in the pouch mucosa are associated with @entity255 found on peroperative liver biopsy specimens at restorative proctocolectomy for XXXX .

entities_list: @entity1 :: ('9606', 'Species') :: ['Patients', 'patients']

entities_list: @entity32 :: ('MESH:D007249', 'Disease') :: ['inflammation']

entities_list: @entity5042 :: ('MESH:D019449', 'Disease') :: ['Chronic pouchitis', 'pouchitis']

entities_list: @entity254 :: ('MESH:C563598', 'Disease') :: ['anastomosis']

entities_list: @entity991 :: ('MESH:D015209', 'Disease') :: ['PSC', 'primary sclerosing cholangitis']

entities_list: @entity31 :: ('MESH:D003093', 'Disease') :: ['ulcerative colitis', 'UC']

entities_list: @entity255 :: ('MESH:D002761', 'Disease') :: ['Cholangitis', 'cholangitis']

answer: @entity31 :: (MESH:D003093,Disease) :: ['ulcerative colitis']


abstract: @entity1475 is an abnormal pregnancy characterized by grossly swollen villi in the absence of a fetus (Kajii and Ohama 1997, Wake et al., 1978, Jacobs et al., 1980). It is well known that this abnormal pregnancy product is androgenetic in origin. The entire genome of the molar conceptus is paternally derived. The majority of moles result from fertilization of an empty egg by haploid sperm. The paternally derived haploid set then duplicated without cytokinesis and restores diploidy. Invariably, this class of moles has a 46, XX karyotype and is completely homozygous for genetic markers. Fertilization of an empty egg by two sperms is responsible for the remaining case. These moles show a mixture of homozygous and heterozygous patterns of paternally derived genetic markers. Although complete mole is usually a benign process, 10 to 20 percent of cases leads to either @entity3 . This propensity to @entity5 has to associate with the genetic features shown in the mole, that imply the formation of homozygosity and the selective inheritance of paternal genome. It has been described in various @entity1 @entity5 that both genetic features associate with the inactivation of @entity5 suppressor genes. Homozygosity would lead to the inactivation of @entity5 suppressor gene in the mole by a signal event occurred on sperm DNAs. In turn, paternal transmission would result in the silencing of particular @entity5 suppressor genes. Thus, @entity5 suppressor genes inactivated either by homozygosity formation or by paternal transmission would be involved in the pathogenesis of @entity1466 . Both the maternal and paternal genomes are necessary for normal embryonic development in mammals. Parental-origin-specific functional differences between two alleles, known as genomic imprinting, seem to be exploited for a regulatory mechanism crucial for the proper development of both embryonic and extraembryonic tissues. The list of imprinted genes identified is growing rapidly lately in @entity19 and @entity1 (DeChiara TM et al., 1991, Barlow et al., 1991, Bartolomei MS et al., 1991, Leff SE et al., 1992, Hatada I et al., 1993, Giddings SJ et al., 1994, Hayashizaki Y et al., 1994, Villar AJ et al., 1994, Guillemot F et al., 1995). Among these, @entity5100 and @entity9037 tightly linked on @entity1 chromosome 11 are of special interest because of their reciprocal imprinting and possible association with certain @entity5 and @entity154 . The @entity5100 gene expressed from the paternally derived allele (Ohlsson et al., 1993, Giannoukalis et al., 1993), whereas the @entity9037 gene is expressed from the maternally derived allele (Rachmilewitz et al., 1992, Zhang et al 1993, Ferguson-Smith et al., 1993).

title: Involvement of @entity5100 and @entity9037 imprinting in XXXX development.

entities_list: @entity154 :: ('MESH:D000013', 'Disease') :: ['congenital abnormalities']

entities_list: @entity5 :: ('MESH:D009369', 'Disease') :: ['tumor', 'malignancy', 'malignancies']

entities_list: @entity1466 :: ('MESH:D002822', 'Disease') :: ['choriocarcinoma']

entities_list: @entity1475 :: ('MESH:D006828', 'Disease') :: ['Complete hydatidiform mole']

entities_list: @entity3 :: ('MESH:D009362', 'Disease') :: ['invasive mole or choriocarcinoma']

answer: @entity1466 :: (MESH:D002822,Disease) :: ['choriocarcinoma']


abstract: A significant determinant for the broad substrate specificity of the metallo-beta-lactamases from @entity2868 and other similar organisms is the presence of a plastic substrate binding site that is nevertheless capable of tight substrate binding in the Michaelis complex. To achieve these two competing ends, the molecule apparently employs a flexible flap that closes over the active site in the presence of substrate. These characteristics imply that dynamic changes are an important component of the mechanism of action of these enzymes. The backbone and @entity2340 side chain dynamics of the metallo-beta-lactamase from @entity2868 have been examined using @entity13140 NMR relaxation measurements. Two states of the protein were examined, in the presence and absence of a tight-binding inhibitor. Relaxation measurements were analyzed by the model-free method. Overall, the metallo-beta-lactamase molecule is rigid and shows little flexibility except in loops. The flexibility of the loop that covers the active site is not unusually great as compared to the other loops of the protein. Local motion on a picosecond time scale was found to be very similar throughout the protein in the presence and absence of the inhibitor, but a significant difference was observed in the motions on a nanosecond time scale (tau(e)). Large-amplitude motions with a time constant of about 1.3 ns were observed for the flexible flap region (residues 45-55) in the absence of the inhibitor. These motions were completely damped out in the presence of the inhibitor. In addition, the motion of a @entity2340 side chain at the tip of the beta-hairpin of the flap shows a very significant difference in motion on the ps time scale. These results indicate that the motions of the polypeptide chain in the flap region can be invoked to explain both the wide substrate specificity (the free form has considerable amplitude of motion in this region) and the catalytic efficiency of the metallo-beta-lactamase (the motions are damped out when the inhibitor and by implication a substrate binds in the active site).

title: Dynamics of the metallo-beta-lactamase from XXXX in the presence and absence of a tight-binding inhibitor.

entities_list: @entity2340 :: ('CHEBI:27897', 'Chemical') :: ['tryptophan']

entities_list: @entity2868 :: ('817', 'Species') :: ['Bacteroides fragilis', 'B. fragilis']

answer: @entity2868 :: (817,Species) :: ['Bacteroides fragilis']